Full Press Release Details
The first and only All-in-one subscription platform offering all of your PR Distribution and Media Outreach Tools in one single solution. Monthly & Annual Subscriptions.
Find & create journalist lists with the most up to date database in the industry.
Personalize and customize your pitch for maximum engagement.
Discover your brand, industry, and competitor mentions.
Now you can track every mention, every conversation, and every shift in sentiment — all from the platform you're already using.
Turn your PR data into actionable intelligence with comprehensive reporting and analytics on every campaign.
Catch issues before our editors do. ACCESS Verified gives you a real-time first pass on your press release so you can submit with confidence — every time.
The first and only All-in-one subscription platform that offers you the ability to manage all of your IR communications needs from a single source. Explore our IR subscriptions
Explore how you can upgrade your IR Site today.
Ensure your IR Site is accessible for your entire audience.
Experience seamless calls with our dedicated team of domestic operators.
Easily send your releases out with quick turnarounds and no extra fees.
Host your day knowing you've got the most experienced webcast team in the industry.
Provide a secure and confidential reporting channel to protect your organization and employees.
Streamline your PR & IR needs with one platform.
Easily schedule and manage your investor meetings with our comprehensive and easy to use software.
Our PR and IR tools are designed to meet all necessary regulatory requirements, giving you the confidence to communicate effectively and compliantly. Streamline your communications needs today with our one-stop shop offering.
Whether a startup or established brand, we deliver the support, targeted distribution, media outreach, and flexible pricing & payment options needed to amplify your story with confidence.
We simplify the process of delivering success for both you and your clients. We understand the importance of getting it right, equipping you with seamless billing, flexible plans and payment structures, and clear reporting and analytics to ensure every campaign runs smoothly and achieves measurable results.
We understand the need to manage high volume of press release distribution efficiently. That's why we offer a dedicated API designed specifically for our legal customers, delivering a streamlined, simple process that ensures value and ease at every step.
We understand the importance of cost efficiency for high-volume partners, which is why we offer bulk discounts tailored to meet your needs while maximizing value.
Designed for brands that need help consistently fueling their content strategy and calendar with optimized press releases, blogs, and more…
Tailored for brands with a solid content strategy seeking support for effectively reaching and engaging the media.
Made for brands that need more comprehensive support building and managing their content strategy, media outreach and engagement plan.
Personalized support to optimize your platform, including tailored journalist list creation, pitch guidance, and monitoring setup.
Continual support and management including ongoing list creation, pitch creation and modifications, monitoring adjustments, and additional reporting and analytics review.
Press Release creation and optimization for SEO and audience engagement
Back to the Newsroom IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia Wednesday, 18 November 2026 08:00 AM
Final participant completes dosing in 170-participant trial; topline results anticipated during the December 2026/January 2027 timeframe
POTOMAC, MD / ACCESS Newswire / November 18, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company"), a clinical-stage biotechnology company developing investigational therapies for Alzheimer's disease, today announced the completion of the six-week treatment phase of CALMA for all its 170 participants.
The final participant has completed dosing, and all required treatment-period visits and assessments are complete. The trial randomized 170 participants with agitation in Alzheimer's dementia across clinical sites in the United States and Canada, exceeding its original enrollment target of 146 participants.
With the treatment phase complete, CALMA is advancing through final data verification, reconciliation, and quality-control activities ahead of database lock, unblinding, and independent statistical analysis.
"Completing treatment and all required treatment-period assessments is a major milestone for CALMA," said Ram Mukunda, Chief Executive Officer of IGC Pharma. "Our focus now shifts to preparing the data for a rigorous, independent analysis. For families living with Alzheimer's dementia, agitation can be among the most difficult symptoms to manage. We are grateful to the patients, caregivers and clinical teams who made this study possible, and we look forward to learning what CALMA tells us about IGC-AD1."
Agitation in Alzheimer's dementia can involve restlessness, pacing, verbal outbursts, and physical aggression. These symptoms can place significant burdens on patients and caregivers and contribute to the need for residential care.
CALMA is a randomized, double-blind, placebo-controlled Phase 2 clinical trial evaluating IGC-AD1, an investigational oral liquid medication, over six weeks of treatment. The primary endpoint measures change in agitation from baseline to Week 6 using the Cohen-Mansfield Agitation Inventory (CMAI). Additional assessments include cognition, caregiver burden, safety, tolerability, and biomarkers.
IGC Pharma is completing the remaining data-management and quality-control activities required for database lock. Following database lock, treatment assignments will be unblinded, and the results will undergo independent statistical analysis under the study's statistical analysis plan. The Company anticipates reporting topline results during the December 2026/January 2027 timeframe, subject to clinical trial and data-management uncertainties.
IGC Pharma, Inc. (NYSE American:IGC) is a clinical-stage biotechnology company developing investigational therapies for Alzheimer's disease and AI-enabled technologies supporting drug discovery, clinical research, cognitive risk assessment and brain-health monitoring. Its lead therapeutic candidate, IGC-AD1, is being evaluated in the Phase 2 CALMA clinical trial for agitation in Alzheimer's dementia. The Company's AI portfolio includes MINT-AD, PRISM and aha, its Agentic Harmonization Assistant, which are being developed to support Alzheimer's research and potential healthcare applications.
This press release contains forward-looking statements, including statements regarding the anticipated timing of database lock, unblinding, independent statistical analysis, the reporting of topline results timeframe, and the future development of IGC-AD1. These forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results, events, and timelines to differ materially. Such risks and uncertainties include delays or changes in data verification, reconciliation, quality-control activities, database lock, unblinding, the availability and scheduling of independent statisticians, and statistical analysis; the possibility that trial results may differ from expectations or may not demonstrate the safety, tolerability, or efficacy of IGC-AD1; and clinical, operational, regulatory, and financing risks described in IGC Pharma's filings with the U.S. Securities and Exchange Commission. The anticipated timing is an estimate and may change as these activities progress. IGC-AD1 is investigational and has not been approved for any indication. The Company undertakes no obligation to update forward-looking statements except as required by law.